1153 ET - Vanda Pharmaceuticals is a potential under-the-radar sleeper hit, says H.C. Wainwright, which initiates coverage of the biopharma's shares with a buy rating and $18 price target. In a research note, analyst Raghuram Selvaraju says he believes generic threats to Vanda's sleep-disorders franchise and the FDA's recent rejection of tradipitant in gastroparesis have obscured the investors' sight of Vanda's underlying value proposition. H.C. Wainwright says Vanda has a well-established commercial portfolio, a pipeline of potentially highly accretive programs and a negative enterprise value, trading at an almost 30% discount to its last reported cash position. Vanda up 2.1% to $4.66. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
October 31, 2024 11:53 ET (15:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.